Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. Surgical complete resection, which is the only radical therapy available, is only possible in a minority of patients who suffer from a locally advanced disease. Radiotherapy can be considered as an adjuvant therapy after surgery or as supportive treatment in palliative care. Attempts are also made at combining it with chemotherapy. In cases of locally advanced, non-resectable or metastatic disease, chemotherapy remains the treatment of choice. The most effective palliative chemotherapy is the pemetrexed plus cisplatin regimen.
INTrodUcTIoN
Pleural mesothelioma is a rare disease with poor prognosis. It accounts for 0.1-0.2% of annual morbidities in Poland, and a similar rate of deaths. It affects males twice as often as females. In 2005 in Poland, 5-year survival did not exceed 18% in female patients and 8% in male patients [1] . Surgery offers radical treatment. Patients with advanced disease, whose general condition is good, are qualified for palliative chemotherapy (CHTH) involving cisplatin (DDP) and pemetrexed (PMT). They usually receive up to 6 cycles of chemotherapy, depending on their tolerance, and are subsequently followed up on for disease progression. No standard second-line treatment has yet been established. Several drugs are routinely used, but there is no scientific evidence as to their superiority over placebo or best supportive care (BSC). We describe cases of 3 patients, treated with the standard first-line chemotherapy regimen of PMT + DDP, in whom disease progression was not reported, and who were subsequently treated with maintenance pemetrexed. In all of them, there was long-term response to the treatment offered, with acceptable toxicity. As standard procedure, vitamin B 12 was administered to the patients every 9 weeks, folic acid was administered daily, and dexamethasone was administered one day before the cytostatic agent, on the day of the cytostatic administration, and on the following day. To assess the response to treatment, modified RECIST (Response Evaluation Criteria in Solid Tumors) criteria were applied [2] . In the first patient diabetes developed during treatment, most probably steroid-induced, and requiring insulin use. In the second patient renal insufficiency (CTCAE v4 grade 1) [3] was observed, which is why treatment had to be discontinued. There have been no significant complications in the third patient to date. The drug was administered to patients suffering from pleural mesothelioma (95% of the subjects) as second or third-line treatment in comparison to placebo. That large multi-centre study involved 571 patients, and failed to demonstrate a significant difference in terms of OS between the two study arms (mOS -7.7 vs. 7.3). There is no data available on PFS and ORR yet (secondary endpoints) [22] .
To sum up, the available second-line therapeutic options in patients with pleural mesothelioma are rather controversial. It appears reasonable that the patients be offered a chance to participate in clinical trials, whenever possible. would not be better to observe the patients involved, and administer appropriate therapy only at the time of disease progression.
That question remains unanswered as of today. To the best of our knowledge, decision on maintenance therapy should be individualized and thoroughly discussed with the patient. There is a need for further prospective randomized studies, but the rarity of pleural mesothelioma remains a limiting factor.
coNcLUsIoNs
The use of maintenance therapy with pemetrexed in the above described cases allowed us to achieve long-term survival in an advanced disease with poor prognosis. It should be emphasized, though, that the management discussed is an experimental treatment that requires further prospective randomized trials.
Doctors and patients are now hopeful of the results of studies on new molecules (phase I trials) [18, 21] . Due to the low incidence of pleural mesothelioma, it is difficult to carry out studies with randomization, and a lot of information on the diagnosis and treatment of the neoplasm comes from prospective studies without randomization.
